Medexus Pharmaceuticals Inc.

As of June 30, 2026, Medexus Pharmaceuticals Inc. carries a market capitalization of 159.25M, placing it among publicly traded companies globally. Its enterprise value stands at 188.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medexus Pharmaceuticals Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Medexus Pharmaceuticals Inc. has 31.66M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.10, and the price-to-book ratio stands at 2.33.

As of June 30, 2026, Medexus Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 8.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 188.93M versus a market cap of 159.25M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Medexus Pharmaceuticals Inc. maintains a current ratio of 1.30, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.62, indicating elevated leverage, while an interest coverage ratio of 3.19 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Medexus Pharmaceuticals Inc. posted a negative return on equity (ROE) of -4.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.60, reflecting losses generated across the asset base. The company generates approximately 1.62M in revenue per employee across its workforce of 90.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.43 indicates how many times Medexus Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Medexus Pharmaceuticals Inc. recorded an income tax benefit of -31,222.62 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -3.39M and -3.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Medexus Pharmaceuticals Inc.'s stock has gained approximately 77.34% over the past 52 weeks. The 50-day moving average sits at 5.01, while the 200-day moving average is 3.72.

Over the twelve months ended June 30, 2026, Medexus Pharmaceuticals Inc. generated 146.61M in revenue and converted that into -3.36M in net income, yielding earnings per share of -0.10. EBITDA reached 22.88M, while operating income came in at 10.07M.

As of June 30, 2026, Medexus Pharmaceuticals Inc. holds 7.58M in cash and equivalents against 37.26M in total debt, resulting in a net debt position of 29.68M. Total book value stands at 68.22M, with working capital of 19.50M providing operational flexibility.

Medexus Pharmaceuticals Inc. produced 20.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -21.36M in capital expenditures, free cash flow totaled -1.17M - equivalent to -0.04 per share.

Over the twelve months ended June 30, 2026, Medexus Pharmaceuticals Inc. posted a gross margin of 54.73, reflecting its pricing power and cost economics. The operating margin of 6.87 and net profit margin of -2.29 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Medexus Pharmaceuticals Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.71: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.54, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Medexus Pharmaceuticals Inc. shareholders.

Medexus Pharmaceuticals Inc.'s most recent stock split took place on December 19, 2018 with a 15:1 split ratio.

As of June 30, 2026, Medexus Pharmaceuticals Inc. has an Altman Z-Score of 1.48, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.